anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This will be a prospective randomized trial of pelvic floor therapy vs. bladder directed therapy. The study target population consists of females, aged 18 to 85 years of age with a clinical diagnosis of IC/BPS and symptoms of chronic urinary frequency, pelvic pain/discomfort, and/or urinary urgency. The approximate number of subjects that will be enrolled in the study is 128, 64 women in each treatment group. Women who satisfy all of the eligibility criteria will be enrolled in the study and randomized to receive bladder treatments (instillation of medications into the bladder) or pelvic floor physical therapy.

Outcome measures will include validated questionnaires, voiding diaries, and Global Response Assessment (GRA). The investigators also will evaluate changes in pelvic floor muscle tone and discomfort pre and post treatment, and their relationship to symptom changes. Finally, the investigators will utilize their well-established urine and serum biomarkers evaluations pre and post treatment to determine if they correlate with symptom change.
Usual care is supported by the use of an interactive e-tool. The e-tool provides psycho-education about sleep and sleep medication, and exercises featuring cognitive behavioural techniques to enhance the self-management of the patient. It's purpose is to motivate patients to discontinue the use of (z-)BZD, to adapt alternative remedies and to support them in this process. The patient can grant the participating GP access to all his answers in the e-tool, making it possible to discuss their findings and experiences face-to-face. During consultations, the GP will also assess the patients' readiness for change and match the appropriate intervention. A tailored gradual taper of the (z-)BZD will be agreed upon, which typically consists of a 10-20% reduction in the daily dose every 2-4 weeks. Follow-up appointments are scheduled depending on the needs of the patient until the end of dose reduction.
NEW MATERIAL:A compound expressed by formula I (R is aryl may be substituted) and salt of said compound. EXAMPLE:1-(1-cyanocyclopropane-1-yl)-1-(2,4-difluorophenyl)-2-(1,2,4-t riazole-1-yl) ethanol. USE:Useful as antifungal agent. Exhibits excellent curative effect for disease of human and animal. Possible to oral administration and has high safety. PREPARATION:For instance, as expressed in the reaction formula, a compound expressed by formula II is reacted in the presence of dehydrating agent (e.g. benzoyl chloride or trifluoroacetic anhydride) and in a solvent at from -78 deg.C to 100 deg.C for 0.1-12hr to afford the compound expressed by formula I.
The study begins with the US phase in which 26 volunteers aged 18 to 50 years will be enrolled to receive an investigational malaria vaccine. The vaccine is made of a malaria protein FMP010 mixed in the adjuvant AS01B. Since this vaccine has not yet been in humans, first, 5 volunteers will get a small (10 µg) dose of FMP010 in AS01B. If it is safe, then 20 volunteers will get 50 µg FMP010 in AS01B. Vaccinations are given IM in the deltoid of the non-dominant arm, every month for 3 months. After each vaccination, the subjects will follow up at clinical trials for evaluation of any adverse events. There will be blood draws to assess safety of the vaccine as well as the level of immune response generated to the vaccine.

Upon receipt of preliminary safety results, the Kenya phase begins in which 30 volunteers who are randomized to receive either 50 µg FMP010 in AS01B (20) or the rabies vaccine (10). Vaccination and is on the same schedule as in the US phase and follow-up is for 112 days.
An effervescent oral vitamin or iron compsn. comprises vitamin C or an iron-contg. cpd., Na2CO3 or NaHCO3, a neutralising agent and K2CO3 as a stabilising agent. The iron cpd. is pref. 1 or more of ammonium iron citrate, sodium ferrous citrate or iron citrate. The neutralising agent is an organic acid, e.g., L-tartaric acid, citric acid, fumaric acid or ascorbic acid.
PURPOSE:To obtain the title compound useful as a preventive and remedy for diseases caused by nerve degeneration by reacting a piperidine compound with an alcohol compound in the presence of a halogenating agent, subjecting the reaction product to ring formation to give a spiro compound. and reducing the spiro compound. CONSTITUTION:A piperidine compound shown by formula I (R<2> is lower alkyl) is reacted with an alcohol compound shown by formula II (R<1> is lower alkyl; *is optically active asymmetric carbon atom) in the presence of a halogenating agent (e.g. N-bromosuccinimide) to give a compound shown by formula III (X is halogen). This compound is treated with a catalytic amount of chlorocobaloxime in the presence of sodium boron hydride to give a spiro compound shown by formula TV. Then this compound is reduced with a reducing agent such as vitride (sodium bis(2-methoxyethoxy)aluminum hydride) to give the objective compound shown by formula V.
INTRODUCTION: Tranexamic acid (TXA) administration is supported by numerous evidence in reducing blood loss after total knee arthroplasty (TKA). The combination of intravenous (IV) and intra-articular (IA) TXA administration revealed good result in blood loss reduction with less evidence of venous thromboembolism event (VTE). Several literature reviews portray that peri-articular (PA) administration yields similar hemostasis in comparison to IV route. However, there is no report on the clinical effect of combining PA + IA TXA in blood loss reduction and its complications, compared to combining IV + IA TXA after TKA.
MATERIALS AND METHODS: We conducted a double-blind, randomized controlled trial comparing the use of PA + IA TXA administration and IV + IA TXA administration in 70 patients who were scheduled for unilateral primary TKA. Thirty-five patients were assigned for PA + IA injection (Group 1) and anoter 35 patients were assigned for IV + IA injection (Group 2). Primary outcomes included total blood loss at 48 h, and the need for blood transfusion. Secondary outcomes included thigh and leg circumference, degree of knee flexion, and postoperative complications.
RESULTS: The calculated blood loss at 48 h showed no difference between Groups 1 and 2 (617 ml vs. 632 ml, p = 0.425). The total hemoglobin and hematocrit changes were not different (1.89 g/dL vs. 1.97 g/dL, p = 0.371 and 5.66% vs. 5.87%, p = 0.391). There was no need for blood transfusion in either group. However, lower thigh swelling was significant in Group 1 (2.15 cm vs. 2.79 cm, p = 0.04). Leg circumferences at 48 h was also lower in Group 1 (42.12 cm vs. 42.77 cm, p = 0.04). There was no significant difference in knee flexion decrease between the two groups (38° vs. 37°, p = 0.425). There were no VTE complications or infections found in either group.
CONCLUSIONS: Combined PA + IA TXA administration had similar efficacy in blood loss reduction and blood transfusion when compared to combined IV + IA TXA. The first group displayed less soft tissue swelling. The combination of PA + IA TXA administration can be used as an alternative regimen to avoid IV TXA administration.
Inflammation can affect the progression of cancer at tumor sites, such as in osteosarcoma, by intensifying metastasis and complicating outcomes. The current diagnostic methods lack the specificity and sensitivity required for early and accurate detection, particularly in differentiating between inflammation-induced changes and tumor activities. To address this, a novel "hedgehog ball"-shaped nanoprobe, Fe3O4@Au-pep-CQDs, was developed and designed to enhance the detection of caspase-1, a key marker of inflammation. This magnetic nanoprobe facilitates simultaneous fluorescence (FL) and electrochemiluminescence (ECL) detection. Magnetic separation minimizes the quenching of nanoparticles in solution and eliminates the need for frequent electrode replacement in ECL tests, thereby simplifying diagnostic procedures. The experimental results showed that in the detection of caspase-1, the nanoprobe had a detection limit of 0.029 U/mL (FL) and 0.033 U/mL (ECL) and had a dynamic range of 0.05 to 1.0 U/mL. Additionally, the nanoprobe achieved high recovery rates of 94.36 to 102.44% (FL) and 94.36-100.12% (ECL) in spiked biological samples. Furthermore, the nanoprobe's capabilities were extended to in vivo bioimaging to provide direct, intuitive visualization of biological processes. These novel nanoprobes were able to significantly enhance the accurate detection of inflammation at tumor sites, thereby optimizing both diagnostic and therapeutic strategies.
Obstructive sleep apnea (OSA) affects quality of life and health in nearly 1 billion patients all over the world. With aging society, OSA increases the risk of Alzheimer's disease and leads to severe cognitive impairment. Chronic intermittent hypoxia (CIH), the core pathological mechanism of OSA, may induce synaptic plasticity damage and cognitive impairment, and decrease learning and memory and attention ability. However, the molecular mechanism underlying OSA is still not fully understood. And, there is no targeted treatment strategy for cognitive impairment in patients with OSA. Firstly, the correlation between OSA and cognitive dysfunction was summarized in this review. Secondly, the molecular mechanism of CIH-induced cognitive impairment was elucidated from the perspectives of synaptic plasticity damage, oxidative stress, inflammation, endoplasmic reticulum stress, apoptosis, mitochondrial dysfunction and autophagy. Finally, the current treatment strategy for cognitive impairment in patients with OSA was summarized.
Participants continued to receive their stable twice daily dose of tacrolimus twice daily on Day 1 through Day 7 and on Day 8 were converted to tacrolimus modified release (MR) once-daily in the morning for 7 days on a 1:1 (mg:mg) basis for their total daily dose. Patients who completed the 2-week pharmacokinetic treatment period were eligible to continue receiving tacrolimus MR as part of the extension treatment period of the study. The extended treatment period began on Day 15 and consisted of a single dose of tacrolimus MR once every morning through the end of the study.
The present invention provides an animal model with overexpression of regucalcin that overexpresses regucalcin, which is inherently expressed in the liver and the like of the higher animal, showing bone pathology typified by osteoporosis. Regucalcin cDNA is cloned from rat liver cDNA library, and cDNA encoding the full-length of regucalcin protein is isolated. ORF is cut from said rat regucalcin full length cDNA and introduced into an expression vector (pCXN2). Said gene expression vector is microinjected to male pronucleus of the fertilized egg of rat. Said fertilized egg is tranplanted into the uterine tube of a host rat to generate rats. Thus, homozygous rats are constructed from said generated rats. Said transgenic rats show remarkable bone pathology, morphologically as well as biochemically, and the body weight gain is suppressed significantly.
Sustained release pharmaceutical tablets are prepared by mixing a solid medicament with a sustained release material in a mixing vessel, heating the vessel until the temperature of the mixture is above the melting point of the sustained release material, coating the mixture until it forms agglomerates, milling the latter, and compressing the milled product into tablets.  The sustained release material is defined as being a lipid material, solid at room temperature, having a melting point of from 40 DEG  to 100 DEG C., substantially water-insoluble and resistant to disintegration, but slowly dispersible in the gastro-intestinal tract.  Suitable such lipids are hydrogenated castor oil, 12-hydroxy-stearyl alcohol, glyceryl mono- and di-stearate, micro-crystalline wax, and mineral or vegetable waxes, and higher fatty acids, higher fatty alcohols (i.e. 12 to 31 carbon atoms) and esters thereof.  Medicaments may be chlorpromazine, aminophylline, secobarbital, acetaminophen, acetylsalicylic acid, tetracycline, vitamins, sympathominetic amines, antihistamines, hematinics, anti-spasmodics, antacids and mono-amine oxidase inhibitors.  Other ingredients may be fillers and tabletting lubricants.  Examples are given for sustained release tablets containing acetaminophen and trans-2-phenylcyclopropylamine, and for a sustained release layered tablet which is a sustained release/immediate release combination containing acetaminophen.
Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with at least one LB symptom (MCI-LB; McKeith, I. G., et al. 2020. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 94(17): 743-55.).
Abstract A nicotine containment pouch 15 is formed from laminates comprising a nicotine barrier layer 20 and a nicotine degradation agent barrier layer 22.  The preferred nicotine barrier layer comprises a nitrile rubber modified acrylonitrile-methyl acrylate copolymer formed by the graft copolymigration of 75 pbw acrylonitrile, and 25 pbw methyl acrylate in the presence of about 10 pbw of a butadiene, acrylonitrile copolymer containing about 70% by weight of polymer units derived from butadiene.  The preferred nicotine degradation agent barrier layer is aluminum.  The exterior surface of the pouch is optionally covered by a protective layer 26 of paper stock or polyethylene terephthalate.      The nicotine barrier layer is bonded to itself about the periphery of a nicotine containing body 34 within the pouch.          SFS/dj
HCT Education participants will receive 1 brief in clinic session prior to discharge home providing education related to symptom management and physical activity, and a wireless activity tracker. HCT Education participants will also receive 6 brief phone calls upon return home.
In this group, participants will receive the PISCES intervention in three sessions; however, the first session will be delivered face to face and the other two via video. The three intervention sessions will be scheduled with a suggested timeline between days 5 and 18 of the hospice admission. The first session will take place in person (suggested timeline 5-7 days after hospice admission). After the first session where the in-person encounter will allow for the establishment of rapport between the interventionist and the caregiver, the second session (suggested timeline 11-13 days after hospice admission) and the third session (suggested timeline 16-18 days after hospice admissions) will be conducted via live videoconferencing. If the caregiver already has access to a computer and Internet, they will utilize the videoconferencing solution. If videoconferencing is not feasible, the sessions will be delivered over the regular phone.
A mitogen activated protein kinase inhibitor peptide which is covalently coupled to a fluorophore/with beta galactosidase or biotinyl enzymes, is new. A mitogen activated protein kinase inhibitor peptide which is covalently coupled to a fluorophore/with beta galactosidase or biotinyl enzymes. The enzymatic sequence is optionally surrounded by spacer. The export and localization sequence for intracellular signalling. The amino acids corresponding to docking domain of a mitogen activated protein kinase and allows the penetration of HIV-type I trans activating transcriptional activator protein in a cell. Independent claims are also included for: (1) a nucleic acid encoding the peptide; (2) a expression vector; and (3) a kit comprising the peptide and/or the expression vector.
The control group will receive the standard care from the community health center. They will not receive a telephone follow-up. They will receive a house call 12 months after recruitment by a trainee, who will conduct the final survey and ask for the " Falls and Events Calendar " given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period). Lastly, they will receive an abbreviated intervention for falling prevention and be given the " Falling Prevention Kit ".
INTRODUCTION: Artificial intelligence (AI) shows immense potential in medicine and Chat generative pretrained transformer (ChatGPT) has been used for different purposes in the field. However, it may not match the complexity and nuance of certain medical scenarios. This study evaluates the accuracy of ChatGPT 3.5 and 4 in providing recommendations regarding the management of postprostatectomy urinary incontinence (PPUI), considering The Incontinence After Prostate Treatment: AUA/SUFU Guideline as the best practice benchmark.
MATERIALS AND METHODS: A set of questions based on the AUA/SUFU Guideline was prepared. Queries included 10 conceptual questions and 10 case-based questions. All questions were open and entered into the ChatGPT with a recommendation to limit the answer to 200 words, for greater objectivity. Responses were graded as correct (1 point); partially correct (0.5 point), or incorrect (0 point). Performances of versions 3.5 and 4 of ChatGPT were analyzed overall and separately for the conceptual and the case-based questions.
RESULTS: ChatGPT 3.5 scored 11.5 out of 20 points (57.5% accuracy), while ChatGPT 4 scored 18 (90.0%; p = 0.031). In the conceptual questions, ChatGPT 3.5 provided accurate answers to six questions along with one partially correct response and three incorrect answers, with a final score of 6.5. In contrast, ChatGPT 4 provided correct answers to eight questions and partially correct answers to two questions, scoring 9.0. In the case-based questions, ChatGPT 3.5 scored 5.0, while ChatGPT 4 scored 9.0. The domains where ChatGPT performed worst were evaluation, treatment options, surgical complications, and special situations.
CONCLUSION: ChatGPT 4 demonstrated superior performance compared to ChatGPT 3.5 in providing recommendations for the management of PPUI, using the AUA/SUFU Guideline as a benchmark. Continuous monitoring is essential for evaluating the development and precision of AI-generated medical information.
PURPOSE: A composition for prevention and treatment of rheumatoid arthritis and osteoarthritis is provided to suppress pain and inflammation of common symptoms in acute and chronic arthritis, and to improve exercise barrier which is a symptom of the chronic arthritis. CONSTITUTION: A composition for prevention and treatment of rheumatoid arthritis comprises an active ingredient mixed with: 350-450 wt% of Kalopanacis Cortex; 350-450 wt% of Chinese quince; 50-150 wt% of first extract which is extracted from Pulvis Aconiti Tuberis Purificatum; 150-250 wt% of Raphani Semen; and 50-150 wt% of second extract which is extracted from Atractylodis Rhizoma. The extract shows an effect which does not have chytotoxin to synoviocyte and chondrocyte. The extract shows effects of improving exercise barrier, and arthritic and analgesia. The extraction solvent for the first extract is 40-60 wt% of alcohol, and the extraction solvent for the second extract is water. [Reference numerals] (AA) Alleviating pain effect
PURPOSE: Assessing vocal cord mobility is crucial for patients undergoing thyroid surgery. We aimed to evaluate the feasibility and efficacy of surgeon-performed transcutaneous laryngeal ultrasound (TLUS) compared to flexible nasolaryngoscopy.
METHOD: From February 2022 to December 2022, we conducted a prospective observational study on patients scheduled for total thyroidectomy at our Institution. All patients underwent TLUS followed by flexible nasolaryngoscopy by a blinded otolaryngologist. Findings were classified as normal or vocal cord movement impairment and then compared. Patients evaluable on TLUS were included in Group A, while those not evaluable were included in Group B, and their features were compared.
RESULTS: Group A included 180 patients, while Group B included 21 patients. Male sex (p < 0.001), age (p = 0.034), BMI (p < 0.001), thyroid volume (p = 0.038), and neck circumference (p < 0.001) were associated with Group B. TLUS showed a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 100%, 99.4%, 94.4%, 100%, and 99.4%, respectively. Cohen's K value was 0.984.
CONCLUSION: TLUS is a valid, easy-to-perform, non-invasive, and painless alternative for evaluating vocal cords in selected patients. It can be used either as a first level exam and as screening tool for selecting cases for flexible nasolaryngoscopy. TLUS should be integrated into routine thyroid ultrasound examination.
All subjects will undergo standard management (colposcopy) for their cervical lesion as scheduled. For cervical sites suspicious of dysplasia, acriflavine hydrochloride 0.05% solution will be applied topically, then rinsed with saline prior to in vivo confocal imaging with the hand-held probe. Following that, a biopsy of the suspicious site will be performed irrespective of the confocal microscopy finding. A biopsy of the normal site will be taken for research purposes. The confocal probe imaging will not alter where and how the biopsies will be taken (no change to size of biopsy or location on cervix).

The procedure will add approximately 15 minutes to the duration of the standard outpatient procedure. During each examination, the anatomical location of all tissue areas in question will be recorded using the clock-position nomenclature system. Some normal areas will be also localized and recorded as control. Digital images will be recorded in the computer.
Post-stroke hemiparesis, with dystonia, is a major cause of disability. Dystonia can hinder the functional activities making patient dependent on others for performance of daily living activities. Dystonia not only limits the physical activity of the patient but also affects their quality of life significantly. Various treatment protocols have been used in the literature for treatment of focal hand dystonia in the past including deep brain stimulation, kinesio taping, sensory oriented training, splinting, extracorporeal shock wave therapy and botox. Out of these Botox has gained much importance but it results only in improving the passive range of motion and has no consensus in improving the active range of motion and functional independence of the patient. The current study was planned to determine the effects of botulinum toxin type A combined with task-specific therapy, for post-stroke focal dystonia of upper limb.
The validity and reliability of the elbow joint position sense with the mobile application will be evaluated with the angle meter. This application works on phones with the IOS operating system. The validity and reliability of the Angle Meter will be evaluated by comparing it with a small universal goniometer for measuring elbow range of motion. The elbows of healthy subjects will be photographed at 3 different angles in the open and kinetic chain position. The elbow photo of healthy individuals measured with the Angle meter will be evaluated simultaneously but independently with the Angle meter by 2 different evaluators. The measurements will be repeated after 3 days. It will be noted that each picture is sufficient, i.e. there is no obvious perspective error.
The following study aims to understand the efficacy of the digital therapeutic, GuessWhat, in improving socialization outcomes in children with Autism Spectrum Disorder (ASD) after regular use over 8 weeks. We will use a cross-over, waitlist control design to examine outcomes after 8 weeks. GuessWhat is a mobile application (available for free for iOS and Android) which contains a suite of games: pro-social charades, emotion guessing, and quiz. Participant families will use their personal smartphones to download the app and play it with their child according to a predetermined regimen. The study will enroll parents who are at least 18 years old and have a child between 3 and 12 years old with a formal ASD diagnosis. Parents will be asked to complete two clinical outcome measure questionnaires immediately prior to and up to 1 week after playing GuessWhat with their child 3 times per week for 8 weeks.